The controversial role of adenoviral-derived vectors in gene therapy programs: where do we stand?

Drug News & Perspectives
Gaetano Romano

Abstract

The high immunogenicity of recombinant adenoviral vectors is one of the major issues in the field of gene therapy. Adenoviral-based vectors are susceptible both to cytotoxic T-lymphocyte and humoral immune responses. In addition, leaky adenoviral genes also render transduced cells susceptible to host immune responses. These are the main reasons why adenoviral-based vectors are not suitable to correct genetic disorders, which require long-term expression of the transgene. Another limit to long-term transgene expression is posed by the fact that adenoviral-based vectors do not integrate their genome into the cellular chromosomal DNA of transduced cell populations. As it stands, adenoviral-mediated gene transfer is a promising tool for cancer therapy and for genetic immunization programs against infectious diseases, provided that host immune responses are carefully controlled.

Citations

Apr 6, 2007·Expert Review of Vaccines·Matthias LinigerHussein Y Naim
Feb 2, 2008·The Journal of Sexual Medicine·Trinity J Bivalacqua, Travis D Strong
May 13, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·A Liras, S Olmedillas
Sep 6, 2013·Epilepsia·Matthew C WalkerLaura Mantoan
Oct 7, 2008·Tissue Engineering. Part B, Reviews·Rob B M de VriesBert Gordijn
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wolfgang WaltherPeter M Schlag

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

© 2022 Meta ULC. All rights reserved